Director Michael Davidson resigns from Silence Therapeutics board

Silence Therapeutics plc

Davidson resigned as director effective August 11, 2025, citing need to focus on other time commitments.
He also stepped down from Audit, Risk, Remuneration, and Science & Technology Committees.
Board reduced from five to four members; Iain Ross appointed to Audit and Risk Committee.
Davidson remains CEO of NewAmsterdam Pharma; resignation not due to any disagreement with the Company.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.